Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases
© Aiken et al; licensee BioMed Central Ltd. 2006
Received: 28 December 2005
Accepted: 30 March 2006
Published: 30 March 2006
New tools are required to improve tuberculosis (TB) diagnosis and treatment, including enhanced ability to compare new treatment strategies. The ELISPOT assay uses Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the immune response to pathogen. We hypothesized that TB patients in The Gambia would have reduced ELISPOT counts after successful treatment.
We recruited Gambian adults with sputum smear and culture positive tuberculosis for ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart, comparing within and between subject variation.
We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive, 77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment: 44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a mean decline of 25, 44 and 47 SFU/2 × 105 cells for CFP-10, ESAT-6 and PPD respectively (p < 0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all 4 not cured subjects (3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months.
Successful tuberculosis treatment is accompanied by a significant reduction in the M. tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is warranted.
Tuberculosis (TB) causes an estimated 2 million deaths per year , the overwhelming majority occur in developing countries , and Mycobacterium tuberculosis infects approximately one third of the world's population . While the incidence of TB has stabilised or is on the decrease in many parts of the world, the incidence rate is rising by approximately 6% per year in Africa . New diagnostic tools for TB, new and enhanced treatment strategies, plus efficacy markers to compare them, are needed to help combat the epidemic. These need to be shown to be useful in TB-endemic tropical settings.
T-cell based immuno-assays have promise for the diagnosis of TB disease and M. tuberculosis infection. The ex-vivo ELISPOT can precisely enumerate interferon-gamma (IFN-γ) producing T-cells sensitised to M. tuberculosis antigens and we have shown that the quantitative ELISPOT count reflects the infectious load of M. tuberculosis in The Gambia . Noting this property, we hypothesized that the ELISPOT count would decrease as a response to a course of anti-TB therapy in TB cases. Therefore, as a first step towards identifying whether the ELISPOT might be an efficacy marker in this way in The Gambia, we assessed the ELISPOT response in TB cases before and after treatment.
Nested in a large case contact study in The Gambia , we recruited sputum smear and culture positive adult TB cases for the study. We took a 10 ml blood sample from each case at the time of diagnosis and followed them up 12 months later to take a repeat sample. The National TB Control Program gave each case a standard six-month course of free treatment by Directly Observed Therapy, short course (DOTS) to all patients. Ethical approval for this study was obtained from the joint MRC – Gambian Government Ethics board. Informed consent was obtained from all study participants.
We tracked the patients' clinical outcome through follow-up interviews and corroborated the results with clinical records (TB treatment cards and clinic treatment register). Patients who were found at follow-up to have successfully completed their treatment, and who were well at time of 12-month blood test (no cough/sweats/weight loss, or other TB symptoms since the completion of treatment), were categorised as "cured." Others were further categorised according to standard WHO definitions : they were defined as "defaulted" if treatment was interrupted for two consecutive months or they were defined as "failed treatment" if they remained sputum smear positive at 4 months or later during a course of treatment.
Sputum smears were prepared and stained with auramine-phenol  and the results were confirmed by Ziehl-Neelsen staining. Decontaminated specimens were inoculated into Lowenstein-Jensen medium and BACTEC 9000 liquid medium for the isolation and identification of M. tuberculosis, as described previously . HIV testing was done by enzyme linked immunosorbent assay (ELISA; Wellcome Laboratories, Dartford, Kent, UK) and by type-specific Western blot (New LAV Blot I and New LAV Blot II, Diagnostics Pasteur, Marnes-la-Coquette, France). All data were entered using double data entry into an ACCESS database and verified.
The ex-vivo ELISPOTs were performed in duplicate as previously described . Overlapping peptides spanning the length of ESAT-6 and CFP-10 (ABC, Imperial College, London, UK) were each divided into peptide pools, and used at 5 μg/ml. Purified Protein Derivative (PPD; Mtb, RT49, Statins Serum Institut, Copenhagen, Denmark) was used at 10 μg/ml. The positive control was Phytohaemaglutinin (PHA; Sigma-Aldrich, UK). Assays were scored by an automated ELISPOT reader (AID-GmbH, Strassberg, Germany). A positive test well was pre-defined as containing at least 10 Spot Forming Units (SFUs) more than, and at least twice as many as, negative control wells. PHA wells were set to at least 150 SFUs above negative control wells, which were required to have less than 30 SFUs to be included in the analysis. Antigen SFUs were reported as number of SFUs above the negative control SFUs.
Reliability of the ELISPOT assay
We assessed the reliability of the ELISPOT assay in two ways. Firstly, to assess the within-subject variability, we tested each antigen in duplicate for each subject and compared the within and the between subject variability by fitting a random effects model for subject. Within our large case contact study, we used ELISPOT results from consecutively recruited TB case contacts: 1223 duplicate results for ESAT-6 peptides and 1182 duplicate results for CFP-10 peptides. For CFP-10 the between subject standard deviation was 29.4 spots and the within subject standard deviation was 3.6 spots. For ESAT-6, the between-subject standard deviation was 38.9 spots and the within-subject standard deviation was 4.2 spots. Therefore the within-subject variability was very small compared to the between-subject variability. Secondly, to assess the day-to-day variability, we recruited 23 adult volunteers from the general community and conducted an ELISPOT test followed by a repeat test after 1 week. Twelve volunteers had a negative test initially: none of these had a positive test after 1 week. Eleven volunteers had a positive test initially: only one of these had a negative test after one week. For those who were positive at both time points the differences between the SFUs at the two time points were: -15, -7, -4, -1, 3, 5, 6, 6, 12, and 35 SFU respectively.
Data management and analysis
All data were entered via double data entry into an Access database and checked for errors. Statistical analysis was conducted using SPSS software. Qualitative outcomes were compared by a test of proportions and quantitative outcomes by student's t-test (paired). When necessary (for ESAT-6 and CFP-10) log (base 10) transformations were performed.
Demographics of 89 smear and culture positive tuberculosis patients
(n = 89)
26 (18 – 80)
Outcome of TB treatment
Completed treatment and cured
Defaulted from treatment
Treatment failed (remained sputum +ve)
Outcome of TB treatment
Completed treatment and cured
Defaulted from treatment
Three HIV-negative cases were defined as "not cured". Two were defined as "defaulted from drug therapy"; both subsequent died with symptoms suggestive of TB recurrence after the 12-month blood test. One case was defined as "treatment failure": he was sputum-smear positive at the end of his six months of TB treatment despite good compliance. All three of these subjects were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months.
Three of four HIV positive cases completed the TB treatment course and were healthy at the time of the 12-month testing. The EC ELISPOT tests in all 3 reverted from positive to negative. One HIV-positive subject defaulted from TB therapy: all three of his ELISPOT tests (CFP-10, ESAT-6 and PPD) were positive at 12 months.
As far as we are aware this is the largest study so far to evaluate ELISPOT reversion after anti-TB treatment. A significant proportion of patients who successfully completed a course of standard TB treatment changed from a positive to a negative EC ELISPOT 12 months after their initial diagnosis. There was also a significant reduction in mean ESAT-6, CFP-10 and PPD ELISPOT counts. Seven per cent of cases had an increase in their ELISPOT counts for either ESAT-6 or CFP-10, compared to 21% for PPD.
The data reported here cannot be explained by the inherent variability of the ELISPOT readout and are consistent with those from other, albeit small, studies from other settings. Two previous studies of tuberculosis patients in the United Kingdom (UK; n = 4) and Italy (n = 18) reported a decline in quantitative ESAT-6 ELISPOT counts after drug treatment [11, 12], However, in one UK study, ESAT-6 ELISPOT counts in 10 patients who had completed TB therapy were marginally but not significantly higher than the counts in 8 different patients early in their TB treatment course .
The ex vivo ELISPOT response is thought to identify recently activated lymphocytes with immediate effector memory that persist only a limited time in circulation once antigen is cleared . It follows therefore that antigen withdrawal after anti-TB therapy would be accompanied by a decline in T cell frequencies. There are several possible explanations why even 'specific' antigen (ESAT-6 and CFP-10) counts did not universally drop below the pre-defined, and relatively conservative, cut-off for positivity (10 SFU) in The Gambia. Firstly, some patients may have been re-exposed to M. tuberculosis after the completion of treatment and re-aquired latent M. tuberculosis infection. Secondly, they may have been exposed to environmental mycobacteria, commonly encountered in the tropics, which share the esat-6 and cfp-10 genes (eg. M. marinum). Thirdly, and most intriguingly, there is evidence that in some individuals there is persistence of a population of activated T cells in the absence of direct mycobacterial antigen stimulation, even for several years after completing therapy .
Having determined that, even in this TB-endemic tropical setting, ELISPOT counts decrease significantly in TB cases after treatment, we will explore the decay kinetics of specific antigen T-cell responses during the course of treatment. It has been suggested that the decay rate of antigen-specific T-cells is approximately 5.5% of the total count per week,  which would lead to an approximately 90% decline in counts over 40 weeks. In a small study in South Africa, Nicol et al showed that 10 children with TB had an initial rise, then a decline in ELISPOT counts over a 6-month treatment course . Vekemans et al, in The Gambia, showed that TB patients had relatively low T cell responses to purified mycobacterial antigens, compared to healthy controls with evidence of M. tuberculosis infection . An obvious explanation for these findings is that patients at diagnosis have suppressed T cell responses because they are unwell. M. tuberculosis can itself interfere with IFN-γ signalling , providing another possible explanation. Other factors may also be important, such as increased early antigen presentation as a result of pathogen killing at the onset of antibiotic therapy. Thus the implied trajectory of cellular kinetics is of T-cell responses that increase early in treatment, then decline as the M. tuberculosis antigen load diminishes. A possible sampling frame would be to conduct repeat ELISPOT tests at 1 month, 2 months (to compare with sputum conversion in smear positive cases), 4 months and 6 months. We also aim to follow those who are persistently ELISPOT positive as a cohort over time.
While it is of interest that all four of the treatment failures (3 HIV-negative, 1 HIV-positive) in our study had positive EC and PPD ELISPOT tests at 12 months, larger numbers of similar cases will be required to identify the true sensitivity of ELISPOT persistence with respect to treatment failure. That a few cured cases had a rise in ELISPOT counts for ESAT-6 and/or CFP-10 suggests that the positive predictive value of this finding for treatment failure is not 100% in The Gambia. However, it is quite possible that 'cured patients' may relapse at a later date.
There is now compelling evidence from a variety of settings that a significant decrease in the ELISPOT count occurs in TB patients that are cured by TB treatment. This may have important implications for clinical practice: effective monitoring of response to treatment, tailoring the duration of anti-tubercular drug therapy, comparing the efficacy of new therapies (including therapeutic vaccines), and rationalising the basis for treatment of latent infection are all possible applications. Further studies are required to define the sensitivity and predictive value of ELISPOT reversion and persistence in relation to TB treatment, to find the best time to conduct a repeat test, and to identify clinical and immunological risk factors for persistence of an ELISPOT response and whether such individuals are at any risk of disease recurrence. A repeat ELISPOT test at 12 months reflects the efficacy of a course of anti-TB treatment even in a TB endemic tropical setting.
We thank the National TB control programme for their ongoing collaboration and the field and laboratory assistants for their hard work.
- Maher D, Raviglione M: Global epidemiology of tuberculosis. Clin Chest Med. 2005, 26: 167-82. 10.1016/j.ccm.2005.02.009.View ArticlePubMedGoogle Scholar
- Raviglione MC, Snider D, Kochi A: Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA. 1995, 273: 220-26. 10.1001/jama.273.3.220.View ArticlePubMedGoogle Scholar
- Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005, 293: 2767-75. 10.1001/jama.293.22.2767.View ArticlePubMedGoogle Scholar
- Global tuberculosis control: sureveillance, planning, financing. WHO report. 2005, Geneva, World Health Organisation (WHO/HTM/TB/2005.349)
- Hill PC, Fox A, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, Donkor SA, Hammond AS, Corrah T, Adegbola RA, McAdam KPWJ, Brookes RH: Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model. Clin Infect Dis. 2005, 40: 273-8. 10.1086/427030.View ArticlePubMedGoogle Scholar
- Jeffries DJ, Donkor S, Brookes RH, Fox A, Hill PC: Design and implementation of relational databases relevant to the diverse needs of a tuberculosis case contact study in The Gambia. Int J Tub Lung Dis. 2004, 8: 1095-99.Google Scholar
- World Health Organisation reports "Monitoring progress towards Millennium Development Goals". [http://www.who.int/tb/publications/global_report/2005/methods/en/index.html]
- Heifets LB, Good RB: Current laboratory methods for the diagnosis of tuberculosis. Tuberculosis: protection, pathogenesis and control. Edited by: Bloom BR. 1994, American Society for Microbiology, Washington DC, 85-110.View ArticleGoogle Scholar
- Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe P, Donkor SA, Hammond AS, Otu J, Corrah T, Adegbola RA, McAdam KP: Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis. 2004, 38: 966-973. 10.1086/382362.View ArticlePubMedGoogle Scholar
- Lalvani AR, Brookes RH, Hambleton S, Britton WJ, Hill AV, McMichael AJ: Rapid Effector Function in CD+ memory T cells. J Exp Med. 1997, 186: 859-65. 10.1084/jem.186.6.859.View ArticlePubMedPubMed CentralGoogle Scholar
- Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex-vivo analysis of antigen-specific IFN-y secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effects of treatment. J Immunol. 2001, 167: 5217-25.View ArticlePubMedGoogle Scholar
- Carrara S, Vincenti D, Petrosillo N, Amiocosante M, Giradi E, Goletti D: Use of a T cell-based assay for monitoring efficacy of anti-tuberculosis therapy. Clin Infect Dis. 2004, 38: 757-9. 10.1086/381754.View ArticleGoogle Scholar
- Ferrand RA, Bothamley GH, Whelan A, Dockrell HM: Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2005, 9: 1034-9.PubMedGoogle Scholar
- Godkin AJ, Thomas HC, Openshaw PJ: Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J Immunol. 2000, 38: 754-756.Google Scholar
- Wu-Hsieh BA, Chen CK, Chang JH, Lai SY, Wu CH, Cheng WC, Andersen P, Doherty TM: Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis. 2001, 33: 1336-40. 10.1086/323044.View ArticlePubMedGoogle Scholar
- Nicol MP, Pienaar D, Wood K, Eley B, Wilkinson RJ, Henderson H, Smith L, Samodien S, Beatty D: Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purifed protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy. Clin Infect Dis. 2005, 40: 1301-8. 10.1086/429245.View ArticlePubMedGoogle Scholar
- Vekemans J, Ota MO, Sillah J, Fielding K, Alderson MR, Skeiky YA, Dalemans W, McAdam KP, Lienhardt C, Marchant A: Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design. Infect Immun. 2004, 72: 381-8. 10.1128/IAI.72.1.381-388.2004.View ArticlePubMedPubMed CentralGoogle Scholar
- Fortune SM, Solache A, Jaeger A, Hill PJ, Belisle JT, Bloom BR, Rubin EJ, Ernst JD: Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependant and -independent mechanisms. J Immunol. 2004, 172: 6272-80.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/6/66/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.